Related Experiment Video
Updated: Jul 26, 2025
05:34
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
718
Renal anemia: current treatments and emerging molecules
1Nephrology Service, Hospital Universitario de Salamanca, Salamanca, Spain.
Revista Clinica Espanola
|June 22, 2023
Summary
New oral treatments targeting prolyl-hydroxylase-hypoxia-inducible factor (PH-HIF) offer an effective alternative for managing anemia in kidney disease patients. These PH-HIF inhibitors show promise, especially for those resistant to traditional erythropoiesis-stimulating agents.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Anemia is a frequent and progressive complication of chronic kidney disease (CKD).
- Renal anemia negatively impacts patient quality of life and increases mortality.
- Current treatments include erythropoiesis-stimulating agents (ESAs), iron, and transfusions.
Purpose of the Study:
- To evaluate novel therapeutic strategies for renal anemia.
- To explore the efficacy of prolyl-hydroxylase-hypoxia-inducible factor (PH-HIF) inhibitors.
Main Methods:
- Clinical trials investigating PH-HIF inhibitors.
- Assessment of hemoglobin levels and treatment efficacy.
- Evaluation of safety profiles for new oral agents.
Main Results:
- PH-HIF inhibitors effectively maintain target hemoglobin levels in patients with renal anemia.
- These agents represent a new oral treatment alternative.
- Long-term safety data are still under investigation.
Conclusions:
- Advances in understanding renal anemia pathogenesis enable new treatments.
- PH-HIF inhibitors offer a promising, effective oral option for renal anemia.
- This approach is particularly relevant for patients resistant to ESAs.
Related Concept Videos
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
40
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
40
01:28Chronic Kidney Disease III: Interprofessional Care
48
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
48
01:25Chronic Kidney Disease I: Introduction
43
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage kidney disease (ESKD). At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate...
43
01:20Acute Kidney Injury V: Interprofessional Care
30
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
30
01:29Renal Regulation of Acid-Base Balance
526
Metabolic reactions in the body produce nonvolatile acids, such as sulfuric acid, which generate an acid load of approximately 1 mEq of H+ per kilogram of body weight daily. Excreting H+ in the urine is essential to balance this acid load.
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
526
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467